Papillary thyroid cancer is the most common type of thyroid cancer. While many patients do well with treatment, some have aggressive forms that are hard to treat. Scientists are looking for new ways to understand and fight these tough cases.
In this study, researchers used computer databases and lab experiments to look at thyroid cancer cells. They found that a protein called plectin is present in higher amounts in cancer tissue compared to normal thyroid tissue. High plectin levels were linked to more aggressive features, like cancer spreading to lymph nodes.
When the researchers blocked plectin in lab-grown thyroid cancer cells, the cells grew more slowly, moved less, and died more easily. This suggests that plectin helps cancer cells survive and spread.
The team also tested a drug called troglitazone, which was once used for diabetes. They found that troglitazone can attach to plectin and slow down cancer cell growth. When they increased plectin in the cells, the drug's effects were weaker, showing that plectin is important for the drug's action.
This is early research, so it's not yet clear if troglitazone can help people with thyroid cancer. More studies are needed to confirm these findings and to see if targeting plectin could be a new treatment approach.
